Key highlights include 14% revenue growth from ongoing businesses and 42% growth in adjusted PBT from ongoing businesses.
Robust balance sheet with net cash at 30 June 2024 £67.8m.
Continued to enhance and streamline portfolio with acquisition of Astutis, and disposals of European Healthcare & MiExact businesses.
Investment in the development of single technology platform for the whole business.
We have delivered another strong year, in line with our strategy with notably strong increases in revenues, profits and cash generation. Margins have also continued to improve strongly. We continued to focus on consolidating our already strong presence in the large, growing and rapidly evolving international GRC markets and significantly enhanced our capabilities with the acquisition of Astutis in the Health, Safety and Environment (‘HSE’) sector. We sold our European Healthcare businesses and MiExact. We now have a higher quality portfolio of growing international businesses and continue to pursue various opportunities to invest in acquisitions to improve our growth and profitability. We have also started to transfer our businesses onto our single operating platform, which will continue to improve our performance. We have had a good start to the current financial year, with revenues and profits in line with expectations.
Chief Executive Officer